
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci is a leading company in the growing field of AI-powered drug discovery and development, with a proven platform for creating novel biologics. Their lead candidate, ABS-201, has the potential to be a best-in-class therapy for a range of indications, including pattern hair loss and endometriosis. Although there are risks associated with clinical development and competition, Absci's differentiated platform and promising clinical data make us optimistic about their future success and the potential of their stock.
Bears say
Absci is a relatively new and unproven company with a high-risk profile due to its early stage clinical trials and lack of established market presence. Additionally, their lead product candidate, ABS-201, may face significant competition in the crowded market for hair loss and endometriosis treatments. Furthermore, the company's financials do not currently support their potential future valuation, making it a risky investment with a negative outlook.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares